TARGIT-A试验中病理前术中放疗治疗早期乳腺癌的局部失败估计
本研究利用TARGIT-A试验病理前队列的已发表生存曲线,通过数字化提取和参数模型估计10年局部失败累积发生率。估计外照射放疗组约1.7%(95%CI 0%-4.3%),风险适应TARGIT策略组约5.5%(95%CI 2.9%-8.0%),仅TARGIT的低危妇女约6.6%(95%CI 3.3%-10.0%),与外照射放疗差异估计为4.9%(95%CI 0.6%-9.2%)。
要点
- TARGIT-A病理前队列10年局部失败估计:外照射放疗约1.7%,风险适应TARGIT策略约5.5%。
- 仅TARGIT治疗的低危妇女10年局部失败约6.6%,与外照射放疗差异估计4.9%(95%CI 0.6%-9.2%)。
- 该数据有助于在兆伏级外照射、千伏级术中放疗或完全省略放疗之间进行情境化决策。
核心结论
- TARGIT-A病理前队列10年局部失败风险外照射放疗约1.7%(95%CI 0%-4.3%),风险适应TARGIT策略约5.5%(95%CI 2.9%-8.0%)。
- 仅TARGIT治疗的低危妇女10年局部失败约6.6%(95%CI 3.3%-10.0%),与外照射放疗差异估计4.9%(95%CI 0.6%-9.2%)。
- 该数据有助于在考虑兆伏级外照射放疗、千伏级术中放疗或完全省略放疗时进行情境化和知情决策。
研究设计与样本
- TARGIT-A是一项实用性随机非劣效性试验,纳入早期乳腺癌妇女,在肿块切除术后接受外照射放疗或50 kV X线术中放疗(根据指征联合或不联合外照射放疗)。
- 本研究使用数字化软件和已发表生存曲线提取局部无复发生存率和总生存率的Kaplan-Meier率,校准至已发表点估计±0.5%以内。
- 数据拟合参数生存模型,总生存曲线与局部无复发生存曲线相减得到竞争死亡风险下的局部失败估计,并使用自助重采样评估参数不确定性。
主要发现
- 10年局部失败风险外照射放疗约1.7%(95%CI 0%-4.3%),风险适应TARGIT策略约5.5%(95%CI 2.9%-8.0%)。
- 仅TARGIT治疗的低危妇女10年局部失败约6.6%(95%CI 3.3%-10.0%),与外照射放疗差异估计4.9%(95%CI 0.6%-9.2%)。
临床怎么用
- 作者指出该数据有助于在考虑兆伏级外照射放疗、千伏级术中放疗或完全省略放疗时进行情境化和知情决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: TARGIT-A was a pragmatic randomized noninferiority trial including women with early-stage breast cancer treated postlumpectomy with either external beam radiation therapy (EBRT) or 50 kV x-rays delivered intraoperatively with or without EBRT, as indicated. The long-term update of the pre-pathology cohort did not include a 10-year estimate of the primary endpoint of local failure (although tabular 5-year data was provided). Here, we used the data from the pre-pathology manuscript to estimate the cumulative incidence of local failure. METHODS AND MATERIALS: Using digitizer software and the published survival curves, we extracted the Kaplan-Meier rate of local recurrence-free survival and overall survival. The extracted data were calibrated to the published point-estimates to within ±0.5%. The data were then fit to parametric survival models, and overall survival and local recurrence-free survival curves were subtracted to give the estimate of local failure in the presence of the competing risk of death. Bootstrap resampling was used to assess for parameter uncertainty in the modeling process. RESULTS: Our analysis estimated that the risk of local failure at 10 years in the TARGIT-A pre-pathology cohort is approximately 1.7% with EBRT (95% confidence interval [CI], 0%-4.3%) and 5.5% in the pragmatic risk-adapted TARGIT strategy (95% CI, 2.9%-8.0%). A weighted average estimate suggests that the risk of local failure in low-risk women treated with TARGIT alone is approximately 6.6% at 10 years (95% CI, 3.3%-10.0%), with an estimated difference of 4.9% (95% CI, 0.6%-9.2%) compared with EBRT. CONCLUSIONS: These data allow for contextualization and informed decisions when considering megavoltage EBRT, kilovoltage intraoperatively, or omission of radiation therapy entirely.
引用
- Ward MC, Bentzen SM, Fasola CE, et al. An Estimate of Local Failure in the TARGIT-A Trial of Pre-pathology Intraoperative Radiation Therapy for Early Breast Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35065848. doi:10.1016/j.ijrobp.2021.12.161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。